Alpha Teknova, Inc. (TKNO)
NASDAQ: TKNO · Real-Time Price · USD
5.05
-0.16 (-3.07%)
Mar 31, 2025, 1:15 PM EDT - Market open

Company Description

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.

The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.

It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.

The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions.

Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Alpha Teknova, Inc.
Alpha Teknova logo
Country United States
Founded 1996
IPO Date Jun 25, 2021
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 173
CEO Stephen Gunstream

Contact Details

Address:
2451 Bert Dr.
Hollister, California 95023
United States
Phone 831 637 1100
Website teknova.com

Stock Details

Ticker Symbol TKNO
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001850902
CUSIP Number 02080L102
ISIN Number US02080L1026
Employer ID 94-3368109
SIC Code 2835

Key Executives

Name Position
Stephen Gunstream President, Chief Executive Officer and Director
Matthew C. Lowell Chief Financial Officer
Damon A. Terrill J.D. General Counsel, Chief Compliance Officer and Secretary
Jennifer Henry Senior Vice President of Marketing

Latest SEC Filings

Date Type Title
Mar 10, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 7, 2025 10-K Annual Report
Mar 4, 2025 8-K Current Report
Nov 8, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Aug 30, 2024 424B3 Prospectus
Aug 29, 2024 EFFECT Notice of Effectiveness
Aug 27, 2024 UPLOAD Filing
Aug 23, 2024 S-1 General form for registration of securities under the Securities Act of 1933
Aug 13, 2024 10-Q Quarterly Report